Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN-881 SAD/MAD in Healthy Subjects
NCT07153146Phase 1Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PN-881 (6 arms), sponsored by Protagonist Therapeutics, Inc. Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2025; status: completed.
02
Drugs
PN-881
Beyond the preview
Go deeper on NCT07153146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153146.